Antibody titre – Page 7 – Communicable Diseases Research

MOG antibody-associated encephalitis secondary to Covid-19: case report

Case Reports

Published on 2021-10-272022-10-27
Journal: BMC Neurology [Category] COVID-19,

MOG antibody-associated encephalitis secondary to Covid-19: case report

Case Reports

Published on 2021-10-272022-10-27
Journal: BMC Neurology [Category] Coronavirus, COVID-19, MERS, SARS,

MOG antibody-associated encephalitis secondary to Covid-19: case report

COVID-19에 이차적 인 MOG 항체 관련 뇌염 : 사례보고

Case Reports

Published on 2021-10-272022-09-01
Journal: BMC Neurology [Category] 진단,

[키워드] Affect affecting Analysis antibody Antibody titer Antibody titre association Atypical Autoimmunity brain MRI Case report cerebrospinal fluid clinical examination CNS Course COVID-19 COVID-19 infection CSF Deterioration Encephalitis executive full recovery headache highlight in some include Infection Inflammation Laboratory laboratory examination lesion male manifestation Methylprednisolone MOG MOG antibody MRI neurological manifestation neurological manifestations Neuropsychology occur outcome Patient patients PCR Prognosis respiratory Respiratory system SARS-CoV-2 serum the disease Treatment unique while
[DOI] 10.1186/s12883-021-02449-5 PMC 바로가기 [Article Type] Case Reports

Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity

Research

Published on 2021-10-112022-10-05
Journal: Nature [Category] SARS, 변종,

[키워드] Affect alleviate analysed Analysis anti-SARS-CoV-2 antibody antibody Antibody titre B.1.351 B.1.617.2 booster both group circulating SARS-CoV-2 variant comparable Comprehensive E484K example Humoral immunity Impact in vitro individual Infection isolate L452R Lineage marker mRNA mRNA vaccine Mutation neutralization neutralization capacity Neutralizing Neutralizing activity nucleocapsid P.1 peptide plasma reached reduction reduction in response retained SARS-CoV-2 SARS-CoV-2 variant specific mutation sustained T cell activation T cell response uninfected vaccination Vaccine vaccine dose vaccine doses Vaccine-induced immunity variant variants while
[DOI] 10.1038/s41586-021-04085-y [Article Type] Research

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

단일 중심 코호트에서 만성 염증 상태 및 면역억제 요법 환자에서 항 SARS-CoV-2 mRNA 백신의 면역원성 및 안전성

Article

Published on 2021-10-012022-09-12
Journal: Annals of the rheumatic diseases [Category] MERS, SARS, 진단,

[키워드] age anti-SARS-CoV-2 antibody Antibody titre Arthritis binding antibody unit Cohort comparable concerning Control COVID-19 disease Effect Efficacy and safety Efficiency ELISA example group healthy control healthy controls IgG immunisation immunogenicity immunosuppressed patient immunosuppressive immunosuppressive therapy in both groups Inflammatory inflammatory condition initial mRNA vaccine mRNA vaccines national guideline Necrosis Neutralising activity pandemic Patient performed Person Protective receiving Rheumatoid risk SARS-CoV-2 severe adverse effect severe disease side Side effect significantly lower Study participants the SARS-CoV-2 therapy titre tumor necrosis factor inhibitors vaccination Vaccinations Vaccine were assessed
[DOI] 10.1136/annrheumdis-2021-220272 PMC 바로가기 [Article Type] Article

Controversy surrounding the Sputnik V vaccine

스푸트니크 V 백신을 둘러싼 논란

Review

Published on 2021-10-012022-09-11
Journal: Respiratory medicine [Category] 변종,

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Articles

Published on 2021-09-112022-10-30
Journal: Lancet (London, England) [Category] COVID-19,

[키워드] 95% CI Academy analyses antibodies antibody Antibody titre antibody titres AstraZeneca AZD1222 baseline boost booster ChAdOx1 nCoV-19 Chinese Clinical research Coalition Cohort Controlled trial Council country COVID-19 vaccine dose Efficacy ELISA Engineering enrolled extended interval finding first dose funding geometric mean titre IgG Immunity immunogenicity data induce Innovation IQR ISRCTN median Medical Science mononuclear cell network NIHR Oxford participant PBMC Peripheral blood persistence phase 2/3 prime-boost interval randomised controlled trial reactogenicity Registered remained Science second dose SFU significantly higher single dose South supply shortage T-cell Response T-cell responses T-cells responses the vaccine titre vaccination Vaccine Valley viral particle Volunteer
[DOI] 10.1016/S0140-6736(21)01699-8 PMC 바로가기 [Article Type] Articles

Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study

Observational Study

Published on 2021-09-012022-10-05
Journal: The Lancet. Healthy longevity [Category] SARS, 임상,

[키워드] ACE2 binding Adaptive immune response age All participant antibody Antibody Response Antibody titre antibody titres B.1.1.7 B.1.351 B.1.351 variant blood sample BNT162b2 Care Cellular immune response cellular response ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Cohort collected correlated correlation country Coverage COVID-19 COVID-19 mortality COVID-19 vaccination COVID-19 vaccine defined Department Evidence extended interval first dose history humoral IgG antibody immune responses immunoassay Impact independent Infection infection with SARS-CoV-2 Interaction IQR kinetic magnitude median median age of BNT162b2 Older P.1 variant P.1 variants participant Participants peptide positive pre-vaccination profile resident response SARS-COV-2 infection SARS-CoV-2 strain second dose serological evidence significantly lower single dose Spike protein spike-specific IgG T-cell Response tested titre vaccination Vaccine vaccine dose variant variants of SARS-CoV-2 were assessed were excluded
[DOI] 10.1016/S2666-7568(21)00168-9 PMC 바로가기 [Article Type] Observational Study

Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study

COVID-19에 대한 입원 후 1년 동안 지속되는 항체 반응: 종단적 코호트 연구

Article

Published on 2021-09-012022-09-11
Journal: Journal of autoimmunity [Category] SARS, 진단, 치료법,

[키워드] 95% CI age analysed Anti-nucleocapsid antibodies Anti-spike anti-spike antibodies anti-spike IgG antibodies antibodies Antibody Response Antibody responses Antibody titers Antibody titre antibody titres association coefficient Cohort cohort of patient conducted COVID-19 cycle threshold defined detectable discharge disease severity evaluated exhibited Hospital stay Hospitalization Hospitalized humoral immune response IgG antibody immune Linear regression Logistic regression longitudinal cohort study nasopharyngeal sample One year Patient positive Post-infection immunity predictor Prospective Prospective Study RT-PCR S-IgG SARS-CoV-2 SARS-CoV-2 RNA seroreversion the antibody response WHO severity score
[DOI] 10.1016/j.jaut.2021.102703 PMC 바로가기 [Article Type] Article

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

SARS-CoV-2 mRNA 백신(BNT162b2) 2회 접종 후 의료 전문가의 조기 항체 반응

Multicenter Study

Published on 2021-09-012022-09-11
Journal: Clinical microbiology and infection : the official [Category] SARS, 임상, 진단, 치료법,

[키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-spike antibodies anti-spike antibody antibody Antibody Response Antibody titre antibody titres baseline Belgium blood sample Blood samples BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine clinical trial collected conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine disease dose dose regimen hcp health-care Humoral response immune response individual individuals infected individual infected individuals lead mRNA vaccine multicentre nucleocapsid of BNT162b2 optimum dose professional reached Receptor binding domain respiratory S1 subunit SARS-CoV-2 SARS-CoV-2 nucleocapsid second dose seronegative severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly higher single dose Spike protein Support the S1 subunit the SARS-CoV-2 the spike protein titre two-dose regimen uninfected Vaccine Volunteer were excluded were measured
[DOI] 10.1016/j.cmi.2021.05.004 PMC 바로가기 [Article Type] Multicenter Study